Although our data showed that LCZ696 and valsartan treatments had a neutral effect on portal-systemic collateral formation and they did not affect intrahepatic VEGF protein expression in portal hypertensive rats, the impact of ARNI treatment on cirrhotic status awaits further exploration. This evidence concerns the gene VEGFA and portal hypertension.